News, Publications & Patents
Publications
Frontiers in Immunology | January 4, 2026
Comprehensive self-antigen screening to assess cross-reactivity in promiscuous
T-cell receptors peptide-coding libraries
In this study, we used our Tope-seq platform to profile massive epitope libraries in live cell assays, detect off-target autoreactivity in a first-pass bulk screen, and demonstrate proof of principle for functional TCR screening of more than 20 million unique peptide-coding DNA fragments.
npj Precision Oncology | August 19, 2024
A synthetic cytotoxic T cell platform for rapidly prototyping TCR function
This study describes the development of a universal prototyping platform to perform TCR profiling in the context of different HLA alleles and broad arrays of potential antigens to ultimately enable safer and faster optimization of therapeutic TCRs.
Nature Communications | October 7, 2019
Rapid selection and identification of functional CD8+ T cell epitopes from large peptide-coding libraries
This publication defines the foundation of Immfinity’s platform and validates a scalable, function-based assay for mapping T-cell epitopes across peptide libraries.
News
News | August 31, 2023
Immfinity places in the top 10 of the New Ventures BC competition
Immfinity was named a top-10 finalist in the 2023 New Ventures BC competition, following last year’s “Diamond-in-the-Rough” win and highlighting our continued momentum.
News | March 31, 2022
Genome BC’s Pilot Innovation Fund Invests in Emerging ‘Omics Innovation
Genome BC’s Pilot Innovation Fund invests in early-stage ‘omics projects, including Immfinity’s Tope-seq, a platform advancing faster, safer T-cell receptor development for immunotherapies.
News | January 20, 2021
Twelve UBC Researchers Receive MSFHR Funding for Patient-Care Research and Commercialization
The awards were announced following two MSFHR competitions focused on supporting projects with strong potential for real-world impact. Among the awardees is Immfinity founding team member Dr. Robert Holt, whose work on T-cell receptor profiling supports the development of next-generation immune therapies.
Patents
Patent-pending | September 12, 2024 | WO2025054720A1
Platforms for characterizing reactivity of T-cell receptors
A synthetic platform for detecting epitopes that are recognized by cytotoxic lymphocytes from a plurality epitopes presented by antigen-presenting reporter cells.
Patent approved | April 21, 2020 | US10627411B2, CA2943569C
T-cell epitope identification
The present invention is a method for determining the identity of the epitopes recognized by T-cells.